High-dose influenza vaccine is 24 percent more effective than the standard-dose vaccine in protecting persons ages 65 and over against influenza illness and its complications, according to a Vanderbilt-led study published today in the New England Journal of Medicine (NEJM).

 

The multi-center study enrolled 31,989 participants from 126 research centers in the U.S. and Canada during the 2011-2012 and 2012-2013 influenza seasons in the Northern Hemisphere in order to compare the high-dose trivalent vaccine versus the standard-dose trivalent vaccine in adults over 65 years of age.

See full paper here http://www.nejm.org/doi/full/10.1056/NEJMoa1315727

 

 

Key Contacts

image - Elizabeth School Photo
Research Associate
T:
+61 (2) 93850082
e.kpozehoven@unsw.edu.au
image - Raina MacIntyre Website Nina KKedit3
Chief Investigator A
r.macintyre@unsw.edu.au